-葡萄糖共传输体-2 抑制剂和异常血清:一个现实世界的药监测研究
Meng Yu1, Subei Zhao2, Xiaoyun Fan1
1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, The First Batch of Key Disciplines on Public Health in Chongqing.
Journal of cardiovascular medicine (Hagerstown, Md.)
|July 1, 2024
概括
在真实世界的数据中,-葡萄糖共传输体-2 抑制剂 (SGLT2i) 显示了高血和低血的减少. 与RAASi或MRA一起使用SGLT2i与单独使用这些药物相比,进一步减少了高血病报告.
科学领域:
- 内分泌学 在内分泌学.
- 药物监督 药物监督 药物监督
- 心血管医学 心血管医学
背景情况:
- 临床试验表明,-葡萄糖共传输体-2 抑制剂 (SGLT2i) 可能会减少高血症.
- 关于SGLT2i和电解质干扰的现实数据有限.
- 研究SGLT2i对水平的影响具有临床意义.
研究的目的:
- 用SGLT2i评估超血和低血的现实发病率.
- 为了比较SGLT2i和其他降血糖药物之间的干扰.
- 评估SGLT2i在与RAASi或MRAs一起使用时对高血症的影响.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据库 (2004-2021) 的回顾性分析.
- 使用报告几率比率 (ROR) 和95%置信区间 (CI) 的不成比例分析.
- 将SGLT2i与其他降糖剂和特定药物组合进行比较.
主要成果:
- 与其他降血糖药物相比,SGLT2i的使用与高胆血症 (ROR 0.83,95% CI 0.79-0.86) 和低胆血症 (ROR 0.79,95% CI 0.75-0.83) 的报告发生率显著降低.
- 与单独使用RAASi (ROR4.40,95%CI4.31-4.49) 相比,在使用SGLT2i与氨酸-氨酸-氨系统抑制剂 (RAASi) (ROR3.25,95%CI3.06-3.45) 的患者中,高卡利米亚报告不成比例地较低.
- 与SGLT2i与矿物质皮质类受体对抗剂 (MRAs) 结合使用时观察到类似的降低高血的趋势.
结论:
- 现实数据证实,与其他糖尿病药物相比,SGLT2抑制剂与高胆血和低胆血的发病率较低有关.
- 将SGLT2i与RAASi或MRA结合使用,进一步减少了高胆固醇血报告的发生.
- 这些发现支持SGLT2i在不同患者群体中的平衡方面有利的安全概况.
相关概念视频
Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Pharmacovigilance
817
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
817
Antiepileptic Drugs: Potassium Channel Activators
168
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
168
Antihypertensive Drugs: Potassium-Sparing Diuretics
511
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Secondary Active Transport
119.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.2K


